Jacobs Bruce N. 4

What Happened Bruce N. Jacobs, Chief Financial Officer of Kymera Therapeutics (KYMR), exercised stock options on 2026-05-18 to acquire 15,000 shares at a $2.08 exercise price, costing $31,200. The same filing shows a simultaneous disposition of 15,000 shares at $0 (derivative), which is recorded in the Form 4. The options underlying the transaction were fully vested and exercisable.

Key Details

• Transaction date: 2026-05-18; Form 4 filed: 2026-05-19 (filed the day after transaction).
• Acquired: 15,000 shares via option exercise at $2.08 each (total $31,200).
• Disposed: 15,000 shares shown as derivative disposition at $0.00 in the filing.
• Footnote: F1 — the shares underlying this stock option are fully vested and exercisable.
• Shares owned after transaction: not specified in the provided filing excerpt.

Context

• This was an option exercise (derivative transaction, code M). A simultaneous acquisition and $0 disposition of the same number of shares commonly reflects a net/cashless exercise or share-surrender to cover the exercise cost or tax withholding; the filing itself records the mechanics but does not show market sale proceeds. Option exercises are routine insider actions and are not the same signal as an open-market purchase or sale.